
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

June 13, 2016

OPKO Health, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-33528

75-2402409

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

4400 Biscayne Blvd., Miami, Florida

33137

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(305) 575-4100

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

[Top of the Form](#)

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On June 13, 2016, OPKO Health, Inc. (the “Company”), in accordance with the authority granted by the Company’s board of directors, provided written notice to the New York Stock Exchange (“NYSE”) of its intention to voluntarily delist its common stock, \$.01 par value per share (“Common Stock”), on the NYSE and to list its Common Stock on the NASDAQ Global Market of The NASDAQ Stock Market LLC (“NASDAQ”). The Company expects the listing and trading of its Common Stock on the NYSE will cease at market close on June 23, 2016, and that trading of its Common stock will commence on NASDAQ on June 24, 2016. The Common Stock has been approved for listing on NASDAQ, with the Common Stock continuing to trade under the symbol “OPK.”

Item 7.01 Regulation FD Disclosure.

On June 13, 2016, the Company issued a press release announcing the transfer to NASDAQ. The press release is furnished as Exhibit 99.1 hereto. The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of the Company dated June 13, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

June 13, 2016

By: Adam Logal

Name: Adam Logal

Title: Senior Vice President-Chief Financial Officer

Exhibit Index

Exhibit No.	Description
99.1	Press Release of the Company dated June 13, 2016



OPKO Health Announces Move to NASDAQ Stock Market

Ticker Symbol to Remain OPK, Trading to Begin June 24

MIAMI (June 13, 2016) – OPKO Health, Inc. (NYSE:OPK) (“OPKO” or the “Company”) announces that it will move its stock exchange listing to The NASDAQ Stock Market from The New York Stock Exchange (the “NYSE”). The Company expects its common stock will begin trading on the NASDAQ Global Select Market (“NASDAQ”) on June 24, 2016, and its shares will continue to trade under the ticker symbol “OPK.”

“NASDAQ is home to many of the world’s best healthcare companies and is a natural fit for OPKO. This move will enhance our public visibility while offering our stockholders cost effective access to advanced trading technologies,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO.

Bob Greifeld, CEO of Nasdaq, said, “Under the leadership of Dr. Frost, OPKO has long been recognized for driving innovation in the pharmaceutical and diagnostics industries to create products that improve our lives. We are proud to welcome the company to Nasdaq.”

The Company has notified the NYSE that it will voluntarily delist its common stock from the NYSE. The last day of trading of the common stock on the NYSE is expected to be on or about June 23, 2016. Until the Company’s Common Stock begins trading on NASDAQ, the Company’s Common Stock will remain trading on NYSE under the ticker symbol “OPK.”

About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform. Our pharmaceutical business features Rayaldee™, a treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D insufficiency and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro, IV formulation (PDUFA: January 2017)). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug for hemophilia (in Phase 2a) and a long acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements regarding the transfer of the listing of the Company’s Common Stock from the NYSE to NASDAQ, the expected start date of trading on NASDAQ, the enhancement of the Company’s public visibility, and the cost effective access to our stockholders of advanced trading technologies. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include the Company’s ability to continue to comply with the NASDAQ listing standards and those described in our filings with the Securities and Exchange Commission. In addition, forward-looking statements may also be adversely affected by general market factors and federal and state regulations and legislation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Company

OPKO Health, Inc.
Tara Mackay, 305-575-4100
Investor Relations

or

Media

Rooney & Associates
Terry Rooney, 212-223-0689
trooney@rooneyco.com

or

Marion Janic, 212-223-4017
mjanic@rooneyco.com

or

Investors

LHA

Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

#